IMGN earnings call for the period ending June 30, 2020.
News & Analysis: ImmunoGen
Momentum is continuing from the biotech's positive pipeline update last week.
The biotech stock bounced back quickly from Friday's sell-off, which followed the release of worse-than-expected first-quarter results.
IMGN earnings call for the period ending March 31, 2020.
Investors appear to be taking profits off the table after the biotech's positive Q4 update.
Cost-cutting led to a surprise profit, and the company outlined the path ahead for its pipeline treatment for ovarian cancer.
The biotech handily beat Wall Street's revenue and earnings estimates.
IMGN earnings call for the period ending December 31, 2019.
Investors in the cancer-focused biotech are hoping for good news next week.
Investors appear to have renewed hopes for the biotech's experimental ovarian cancer drug.